FORMULATION AND EVALUATION OF LINAGLIPTIN BUCCAL ADHESIVE TABLETS FOR TYPE-II DIABETES

Last few decades, the remarkable advancement in the drug delivery system has been done; the oral route remains the importance and picks up the safest route of drug delivery. Regardless of striking advancements in the oral route medication, the current study focused on the formulation of a linagliptin buccal adhesive tablet. Formulated tablets are containing linagliptin as an active drug with a combination of different polymers such as carbopol (CP), eudragit RL-100 (EU), sodium alginate (SA) at different compositions with an impermeable backing layer of ethyl cellulose (EC). The formulation was carried out by direct compression, and tablets were evaluated by different parameters for pre and post-compression study. The post-compression evaluation parameters are weight variation test, hardness, thickness, friability, drug content, swelling index, pH followed by in-vitro drug release studies at pH 6.8. Compatibility study between drug-polymerr interactions was investigated by FTIR studies. Formulation F6, which contains a high concentration of EU provides maximum prolong the release of linagliptin among all other formulations. Formulation F6 has shown better control of drug release 100% at 12 h. Obtained results concluded that the composition of hydrophobic and hydrophilic polymers at different ratios could be a good matrix for controlling the release rate of linagliptin buccal adhesive tablet in a prolong manner and bypass hepatic metabolism to improve bioavailability of linagliptin. In-vitro release kinetic study carried out for all the formulations and followed diffusion and erosion mechanism.